Clinical Trial Update: Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and immunogenicity of a single-vial R21/Matrix-M malaria vaccine, co-administered with EPI vaccines; the trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• R21/Matrix-M malaria vaccine (R21/Matrix-M malaria vaccine)

Snippet

Sponsor: University of Oxford | Conditions: Malaria | Phase 1 | Status: COMPLETED